Comparison of Immune Globulin Intravenous (Human), 10% (IVIG), plus Rituximab vs. IVIG 10% + Placebo (Normal Saline) as Agents to Reduce Donor Specific Antibodies, Improve Transplant Rates and Outcomes in Highly-HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation

Grant

Awarded By

Total Award Amount

  • 0.00

    • Direct Costs

  • 0.00

    • Sponsor Award Id

    • Contributor

  • Jayme Locke   Investigator  
  • Shikha Mehta   Investigator  
  • Vineeta Kumar   Investigator